{"prompt": "['Investigational Product (KPT-330)', 'Karyopharm Therapeutics Inc.', 'Clinical Study Protocol: KCP-330-023', '17 August 2018', '11.4.1.', 'Pharmacokinetic Endpoints', '80', '11.4.2.', 'Pharmacodynamic Studies', '81', '11.4.2.1.', 'Bone Marrow Aspirates for PDn', '81', '11.5.', 'Safety Assessments', '81', '11.5.1.', 'Clinical Safety Assessments', '81', '11.5.1.1.', 'Weight, Height, and BSA', '81', '11.5.1.2.', 'Physical Examination, Vital Signs, and ECOG Performance Status', '81', '11.5.1.3.', 'Electrocardiography', '82', '11.5.1.4.', 'Ophthalmic Examination', '82', '11.5.1.5.', 'Concomitant Medications', '83', '11.5.1.6.', 'Adverse Events', '83', '11.5.2.', 'Laboratory Safety Assessments', '83', '11.5.2.1.', 'Clinical Laboratory Tests', '83', '11.5.2.2.', 'Pregnancy Testing', '84', '11.6.', 'QoL Assessments', '84', '11.7.', 'Other Assessments', '85', '11.7.1.', 'C-reactive Protein and Collection of Information on Antineoplastic Therapy', '85', '11.7.2.', 'Nutritional Consultation', '85', '11.7.3.', 'Telephone Contacts', '85', '11.7.4.', 'Durability of Response and Survival Follow-up Visit(s)', '85', '12.', 'SAFETY DEFINITIONS, RECORDING, AND REPORTING', '86', '12.1.', 'Adverse Events', '86', '12.1.1.', 'Definitions', '86', '12.1.2.', 'Recording of Adverse Events', '86', '12.1.2.1.', 'Laboratory Test Abnormalities', '87', '12.1.2.2.', 'Adverse Events of Special Interest', '87', '12.1.2.3.', 'Other Adverse Events', '87', '12.1.3.', 'Adverse Event Severity', '88', '12.1.4.', 'Adverse Event Causality', '88', '12.2.', 'Serious Adverse Events', '88', '12.2.1.', 'Events that Do Not Meet the Definition of a Serious Adverse Event', '89', '12.2.2.', 'Recording of Serious Adverse Events', '89', '12.2.3.', 'Reporting of Serious Adverse Events', '89', 'Confidential', 'Page 8', 'Version 4.0']['Investigational Product (KPT-330)', 'Karyopharm Therapeutics Inc.', 'Clinical Study Protocol: KCP-330-023', '17 August 2018', '12.2.4.', 'Suspected Unexpected Serious Adverse Reactions', '90', '12.3.', 'Procedures for Handling Special Situations', '90', '12.3.1.', 'Pregnancy and Breastfeeding', '90', '12.3.2.', 'Overdose, Abuse, Misuse, Medication Errors, and Occupational Exposure', '91', '12.3.2.1.', 'Overdose', '91', '12.3.2.2.', 'Abuse, Misuse, or Medication Error', '92', '12.3.2.3.', 'Occupational Exposure', '92', '13.', 'STATISTICAL METHODS', '93', '13.1.', 'General Considerations', '93', '13.2.', 'Determination of Sample Size', '93', '13.2.1.', 'Interim Analyses', '93', '13.2.1.1.', 'Interim Analysis of PFS for Sample Size Re-estimation', '93', '13.2.1.2.', 'Interim Analysis of PFS for Futility or Superiority', '94', '13.3.', 'Analysis Populations', '94', '13.3.1.', 'Intent-to-Treat Population', '94', '13.3.2.', 'Per-protocol Population', '94', '13.3.3.', 'SVdX (Crossover from Vd) Population', '94', '13.3.4.', 'SdX (Crossover from Vd) Population', '95', '13.3.5.', 'Safety Population', '95', '13.4.', 'Data Analysis and Presentation', '95', '13.4.1.', 'Procedures for Handling Missing Data', '95', '13.4.2.', 'Patient Disposition', '95', '13.4.3.', 'Demographic Characteristics', '96', '13.4.4.', 'Baseline Characteristics and Medical History', '96', '13.5.', 'Efficacy Analysis', '96', '13.5.1.', 'Primary Analysis for PFS', '96', '13.5.2.', 'Analyses of the Key Secondary Endpoints', '97', '13.5.2.1.', 'Overall Response Rate', '97', '13.5.2.2.', 'Incidence of Any Grade >2 Peripheral Neuropathy Events', '98', '13.5.2.3.', \"Response Rate for Responses >VGPR Based on the IRC's Assessment\", '98', '13.5.3.', 'Analyses of the Non-Key Secondary Effiacy Endpoints', '98', '13.5.4.', 'Exploratory Analyses', '99', '13.6.', 'Pharmacokinetic Analysis', '100', 'Confidential', 'Page 9', 'Version 4.0']\n\n###\n\n", "completion": "END"}